Drug and Therapeutics Bulletin 2008;46:49-52; doi:10.1136/dtb.2008.06.0014
Copyright © 2008 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
PubMed
Right arrow PubMed Citation

Three new drugs for type 2 diabetes

Relevant BNF section: 6.1.2.3

For many patients with type 2 diabetes mellitus, metformin plus appropriate treatment for cardiovascular risk factors form the cornerstone of drug therapy.1 However, the progressive impairment of both the secretion and action of insulin in the condition mean that high blood glucose concentrations usually worsen over time, so necessitating escalation of hypoglycaemic therapy.1 Three drugs in two new classes that act on the hormonal regulation of insulin secretion have been launched recently for use as add-in therapies in patients with type 2 diabetes: {blacktriangledown}exenatide (Byetta – Eli Lilly), {blacktriangledown}sitagliptin (Januvia – MSD), and {blacktriangledown}vildagliptin (Galvus – Novartis). Here we consider whether they have a role in the management of such individuals.




This article has been cited by other articles:


Home page
 DTBHome page
Tests for equivalence or non-inferiority - why?
DTB, July 1, 2008; 46(7): 55 - 56.
[Abstract] [Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2008 BMJ Publishing Group Ltd.